Fiche publication
Date publication
janvier 2026
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FUMET Jean-David
Tous les auteurs :
Selle F, Rodrigues M, You B, Gladieff L, Hardy-Bessard AC, de la Motte Rouge T, Fumet JD, Le Saux O, Colombo PE, Ferron G, Treilleux I, Rouleau E, Falandry C, Joly F, Frénel JS, Quesada S, Classe JM
Lien Pubmed
Résumé
The evolution of serous high grade ovarian cancer management is characterized by a more regulated patients' journey on the one hand and the development of new therapeutic options on the other hand, the selection of which is guided by tumor molecular characteristics. Surgery remains the cornerstone of treatment. It can be performed only in authorized expert sites that can demonstrate sufficient experience from highly skilled surgical teams, and quality criteria including prehabilitation and rehabilitation programs. The diagnostic step is crucial; it comprises multiple biopsies that allow reliable pathological and molecular analyses, and a comprehensive surgical staging. Determination of BRCA1/2 mutation and homologous recombination deficiency statuses by validated methods guide maintenance therapy at advanced stages and referring to oncogenetic consultation if appropriate. For these advanced diseases, the two main questions for surgical strategy are the feasibility of complete resection (without residual disease, CC-0), assessed during surgical exploration of pelvis and abdomen, and the optimal timing of this surgery (upfront or after neoadjuvant chemotherapy). In recurrent diseases, surgery remains a main piece of treatment in case of late relapse and medical treatment depends on drugs used in the first line; in early platinum resistant relapse, a new therapeutic option is available with mirvétuximab soravtansine.
Mots clés
BRCA1/2, Cancer de l’ovaire séreux de haut grade, Chirurgie, High grade serous ovarian cancer, Homologous recombination status, Inhibiteurs de PARP, Mirvétuximab soravtansine, PARP inhibitors, Statut recombinaison homologue, Surgery
Référence
Bull Cancer. 2026 01 30;:
